GLP-1 / Weight Management
Orforglipron
Orforglipron is a first-in-class oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide which requires absorption enhancers, orforglipron is a small molecule with inherent oral bioavailability. Phase 3 clinical trials are evaluating its efficacy for weight management and type 2 diabetes, with early data showing clinically meaningful weight reductions and glycemic improvements.
Quick Facts
Also known asLY-3502970
CategoryGLP-1 / Weight Management
Half-life~1 day
Routesoral
Molecular weight882.974 Da
FDA statusNot approved
StorageRoom temperature (15-25°C). Reconstituted: 90 days.
Dosing Protocols
| Goal | Dose | Frequency | Route | Cycle | Notes |
|---|---|---|---|---|---|
| Type 2 Diabetes Initiation | 3 mg | 1x/day | oral | Continuous | 3 mg daily oral tablet. Long-term continuous. Anytime with or without food. |
| Type 2 Diabetes Moderate Control | 12 mg | 1x/day | oral | Continuous | 12 mg daily oral tablet. Long-term continuous. |
| Type 2 Diabetes Optimal Control | 36 mg | 1x/day | oral | Continuous | 36 mg daily oral tablet. Long-term continuous. HbA1c reductions 1.3-1.6%. |
| Weight Loss Initiation | 6 mg | 1x/day | oral | Continuous | 6 mg daily oral tablet. Long-term continuous. |
| Weight Loss Optimization | 36 mg | 1x/day | oral | Continuous | 36 mg daily oral tablet. 12.4% weight loss in ATTAIN-1 trial at 72 weeks. |
Protocols shown are for informational purposes only. Consult a healthcare provider before starting any peptide protocol.
Track Your Orforglipron Protocol
Log doses, manage vial inventory, set injection reminders, and visualize blood concentration levels.
Start Tracking — FreeCommon Questions
What is the typical dose of Orforglipron?
A common dose for Orforglipron is 3 mg 1x/day via oral. 3 mg daily oral tablet. Long-term continuous. Anytime with or without food.
What is the half-life of Orforglipron?
The half-life of Orforglipron is approximately ~1 day. This determines how long the peptide remains active in your body and influences dosing frequency.
How should I store Orforglipron?
Store Orforglipron at Room temperature (15-25°C). Oral non-peptide small molecule. Store in original packaging at room temperature. No reconstitution required. Investigational compound. Once reconstituted, use within 90 days.
Is Orforglipron FDA approved?
Orforglipron is not FDA approved and is available for research purposes only. It has not been evaluated by the FDA for safety or efficacy in humans.
References
- ATTAIN-1 Phase 3 - 3127 adults with obesity, 72 weeks (article)
- ATTAIN-2 Phase 3 - 1613 adults with obesity + T2DM, 72 weeks (article)
- ACHIEVE-1 Phase 3 - 559 adults with T2DM, 40 weeks (article)
- Phase 2 Obesity - 272 participants, 36 weeks, up to 14.7% weight reduction (article)
- Phase 2 T2DM comparison to dulaglutide (2023) (article)